Journal article

MUC13 protects colorectal cancer cells from death by activating the NF-κB pathway and is a potential therapeutic target

YH Sheng, Y He, SZ Hasnain, R Wang, H Tong, DT Clarke, R Lourie, I Oancea, KY Wong, JW Lumley, TH Florin, P Sutton, JD Hooper, NA McMillan, MA McGuckin

Oncogene | NATURE PUBLISHING GROUP | Published : 2017

Abstract

MUC13 is a transmembrane mucin glycoprotein that is over produced by many cancers, although its functions are not fully understood. Nuclear factor-κB (NF-κB) is a key transcription factor promoting cancer cell survival, but therapeutically targeting this pathway has proved difficult because NF-κB has pleiotropic functions. Here, we report that MUC13 prevents colorectal cancer cell death by promoting two distinct pathways of NF-kB activation, consequently upregulating BCL-X(L). MUC13 promoted tumor necrosis factor (TNF)-induced NF-κB activation by interacting with TNFR1 and the E3 ligase, cIAP1, to increase ubiquitination of RIPK1. MUC13 also promoted genotoxin-induced NF-κB activation by inc..

View full abstract

Grants

Awarded by National Science Foundation


Funding Acknowledgements

This work was supported by the Australian National Health and Medical Research Council (NHMRC) project grant 1060698 and by funding from the Mater Foundation. MAM is supported by an NHMRC Principal Research Fellowship. The Translational Research Institute (TRI) is supported by a grant from the Australian Government. We acknowledge the technical assistance of the TRI core facilities for flow cytometry, microscopy and biological resources. We thank Michael R Tallack for help with Chip analysis and John Silke for providing feedback on our manuscript.